LRPAP1 and B-cell chronic lymphocytic leukemia: Finally, a significant decrease in MEC1 and primary CLL proliferation was noted upon rapamycin, AZD8055, and RAP/IB combination treatment compared to NDC (Fig. 6G, H & Supplementary Fig. 11I, J).